Molecular Formula | C19H25N3O4 |
Molar Mass | 359.42 |
Density | 1.216±0.06 g/cm3(Predicted) |
Melting Point | 92-93 °C |
Boling Point | 532.6±50.0 °C(Predicted) |
Solubility | DMSO: 10 mg/mL |
Appearance | solid |
Color | tan |
pKa | 10.07±0.48(Predicted) |
Storage Condition | 2-8°C |
In vitro study | The effect of BN82002 on cell proliferation is evaluated in vitro on several human tumor cell lines. Menadione, which has been reported to inhibit cell proliferation, is used as a control. All of the examined cell lines are sensitive to BN82002 and Menadione in a concentration-dependent manner in the low micromolar range. The most sensitive is the pancreatic cancer cell line MIA PaCa-2 with an IC 50 of 7.2 μM, and the less sensitive cell line is the colon cancer HT-29 with an IC 50 of 32.6 μM. The range of activity is very similar to the one observed with menadione (5-15 μM). It is also showed that 50 μM BN82002 is a concentration that fully inhibits cell proliferation, the cell cycle distribution is only modestly affected with a slight decrease in S phase and an increase in cells containing both a G1 and a G2 DNA content, suggesting that the cells treated with BN82002 are arrested at various stages of the cell cycle. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.526 ml | 12.63 ml | 25.26 ml |
5 mM | 0.505 ml | 2.526 ml | 5.052 ml |
10 mM | 0.253 ml | 1.263 ml | 2.526 ml |
5 mM | 0.051 ml | 0.253 ml | 0.505 ml |
biological activity | BN82002 is a potent, selective, and irreversible pan-inhibitor of the CDC25 phosphatase family. BN82002 inhibited CDC25A,CDC25B2,CDC25B3,CDC25C CDC25A and 25C-cat with IC50 values of 2.4, 3.9, 6.3, 5.4 and 4.6 μm, respectively. BN82002 showed approximately 20-fold higher selectivity than CD45 tyrosine phosphatase. |
Target | IC50: 2.4 μm (CDC25A), 3.9 μm (CDC25B2), 6.3 μm (CDC25B3), 5.4 μm (CDC25C), 4.6 μm (CDC25C-cat). |